No headlines found.
PRNewswire (Thu, 21-Mar 8:52 AM ET)
Kazia announces presentation of new data at AACR Annual Meeting
PRNewswire (Wed, 13-Mar 8:00 AM ET)
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
PRNewswire (Wed, 21-Feb 7:30 AM ET)
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
PRNewswire (Thu, 18-Jan 7:30 AM ET)
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Kazia Therapeutics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol KZIA.
As of March 28, 2024, KZIA stock price declined to $0.28 with 40,568 million shares trading.
KZIA has a beta of -0.26, meaning it tends to be less sensitive to market movements. KZIA has a correlation of 0.00 to the broad based SPY ETF.
KZIA has a market cap of $7.38 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, KZIA stock traded as high as $14.89 and as low as $.19.
KZIA has underperformed the market in the last year with a return of -70.9%, while the SPY ETF gained +33.7%. In the last 3 month period, KZIA fell short of the market, returning -34.9%, while SPY returned +10.1%. However, in the most recent 2 weeks KZIA has outperformed the stock market by returning +24.9%, while SPY returned +1.7%.
KZIA support price is $.29 and resistance is $.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KZIA stock will trade within this expected range on the day.